Good News | Healrna is recognized as a potential unicorn enterprise in Jiangsu Province

On September 24th, the Jiangsu New Quality Productivity Promotion Center officially announced the assessment results of Jiangsu unicorn enterprises in 2025. Healrna was successfully selected as a potential unicorn enterprise in Jiangsu due to its solid biotechnology and strong strategic soft power, injecting new impetus into the biotechnology and new pharmaceutical industries. 

The "Potential Unicorn Enterprises in Jiangsu Province" refer to those registered in Jiangsu, possessing strong technological innovation vitality and representing the development direction of emerging industries. These enterprises have breakthrough technologies and huge market potential, and are rapidly growing into leaders in their respective industries. They play a significant role in promoting economic development in Jiangsu and across the country, as well as in facilitating industrial upgrading and technological innovation. A total of 525 potential unicorn enterprises were selected throughout the province this time. Healrna stood out among many enterprises by virtue of its in-depth research and breakthroughs in the fields of infectious disease vaccines, tumor vaccines, and cell therapy.

As a high-tech enterprise specializing in the research and production of mRNA drugs, Healrna has always focused on the delivery system platform, mRNA design platform and production process platform as its core, building a complete chain capability covering drug design, process development and industrialization production, and is committed to providing innovative solutions for major infectious diseases and cancer treatment.

Looking to the future,Healrna will continue to increase its investment in research and development, accelerate the process of converting scientific achievements into clinical applications, and actively respond to the Healthy China and Biomedical Innovation strategies. It will inject continuous "Healrna strength" into the high-quality development of the vaccine and treatment fields across the country and globally.